Sandoz Timolol Ophthalmic Solution Recalled Due to Potential Health Risk
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Sandoz Timolol Ophthalmic Solution Recalled Due to Potential Health Risk

OTTAWA, Ontario -- July 18, 2008 -- Health Canada is warning patients not to use the prescription drug Sandoz Timolol Ophthalmic Solution in 0.25% and 0.5% strengths because some bottles may contain more of the active ingredient (timolol maleate) than indicated on the label, exposing patients to an increased risk of adverse events.

Sandoz Timolol Ophthalmic Solution 0.25% and 0.5% are eye drops taken for the treatment of increased intraocular pressure and glaucoma.

Potential adverse events may include red eye, eye irritation, inflammation of the eyelids and/or cornea, drooping of the upper eyelid, double vision, dizziness, headache, abnormally slow heartbeat, abnormally low blood pressure, shortness of breath, difficulty breathing, and cardiac failure.

Patients taking either Sandoz Timolol Ophthalmic Solution 0.25% or 0.5% eye drops should discontinue use and consult their healthcare practitioner immediately to ensure that treatment of intraocular pressure is not interrupted. Patients should return the product to their pharmacist for safe disposal.

The manufacturer, Sandoz Canada Inc., is recalling the products, and Health Canada is continuing to monitor the effectiveness of this recall.

Patients requiring more information about this advisory can contact Health Canada's public enquiries line at 613-957-2991 or toll free at 1-866-225-0709.

To date, no cases of adverse reactions linked to the use of this product have been reported in Canada. To report a suspected adverse reaction to this product, please contact the Canada Vigilance Program of Health Canada by one of the following methods:

Telephone: 1-866-234-2345
Facsimile: 1-866-678-6789
Canada Vigilance Program
Mail: Marketed Health Products Directorate
Ottawa, Ontario, AL 0701C
K1A 0K9
E-mail: CanadaVigilance@hc-sc.gc.ca

SOURCE: Health Canada

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities